Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

Published:2015-06 Issue:9 Volume:90 Page:755-768
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Gambacorti‐Passerini Carlo¹,Kantarjian Hagop M.²,Kim Dong‐Wook³,Khoury Hanna J.⁴,Turkina Anna G.⁵,Brümmendorf Tim H.⁶⁷,Matczak Ewa⁸,Bardy‐Bouxin Nathalie⁹,Shapiro Mark¹⁰,Turnbull Kathleen¹⁰,Leip Eric¹⁰,Cortes Jorge E.²

Affiliation:

1. Department of Internal MedicineUniversity of Milano‐BicoccaMonza Italy

2. Department of LeukemiaDivision of Cancer MedicineUniversity of Texas MD Anderson Cancer CenterHouston Texas

3. Department of HematologySeoul St. Mary's HospitalSeoul South Korea

4. Division of HematologyWinship Cancer Institute of Emory UniversityAtlanta Georgia

5. Hematology Research CenterMoscow Russia

6. Clinic for OncologyHematologyand Stem Cell TransplantationUniversitätsklinikum Aachen, RWTH Aachen Germany

7. OncologyHematologyand Stem Cell TransplantationUniversitätsklinikum Hamburg‐EppendorfHamburg Germany

8. PfizerNew York New York

9. Pfizer Global Research and DevelopmentParis France

10. PfizerCambridge Massachusetts

Funder

MD Anderson Cancer Center Support Grant

National Cancer Institute Award

Italian Association for Cancer Research Grant

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24034

Reference41 articles.

1. Chronic Myelogenous Leukemia: Biology and Therapy

2. Characteristics of accelerated disease in chronic myelogenous leukemia

3. Advanced-phase chronic myeloid leukemia

4. Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

5. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—Comparison with historic experience

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Boosting synergism of chemo- and immuno-therapies via switching paclitaxel-induced apoptosis to mevalonate metabolism-triggered ferroptosis by bisphosphonate coordination lipid nanogranules;Acta Pharmaceutica Sinica B;2024-02

2. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study;Annals of Hematology;2023-08-18

3. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study;Haematologica;2023-07-13

4. Imatinib Analogs in Chronic Myeloid Leukemia: a Systematic Qualitative Review;Current Pharmacology Reports;2023-04-10

5. The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective;Indian Journal of Medical and Paediatric Oncology;2022-11-28